company background image
301246 logo

Hubei Hongyuan Pharmaceutical Technology SZSE:301246 Stock Report

Last Price

CN¥13.41

Market Cap

CN¥5.3b

7D

-8.1%

1Y

-53.6%

Updated

13 Oct, 2024

Data

Company Financials

Hubei Hongyuan Pharmaceutical Technology Co., Ltd.

SZSE:301246 Stock Report

Market Cap: CN¥5.3b

301246 Stock Overview

Engages in the production and sale of pharmaceutical products in China and internationally.

301246 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends1/6

Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hubei Hongyuan Pharmaceutical Technology
Historical stock prices
Current Share PriceCN¥13.41
52 Week HighCN¥29.40
52 Week LowCN¥10.58
Beta0
11 Month Change21.91%
3 Month Change1.13%
1 Year Change-53.57%
33 Year Changen/a
5 Year Changen/a
Change since IPO-68.03%

Recent News & Updates

Subdued Growth No Barrier To Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246) With Shares Advancing 38%

Oct 08
Subdued Growth No Barrier To Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246) With Shares Advancing 38%

Hubei Hongyuan Pharmaceutical Technology Co., Ltd.'s (SZSE:301246) P/S Still Appears To Be Reasonable

Aug 23
Hubei Hongyuan Pharmaceutical Technology Co., Ltd.'s (SZSE:301246) P/S Still Appears To Be Reasonable

Recent updates

Subdued Growth No Barrier To Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246) With Shares Advancing 38%

Oct 08
Subdued Growth No Barrier To Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246) With Shares Advancing 38%

Hubei Hongyuan Pharmaceutical Technology Co., Ltd.'s (SZSE:301246) P/S Still Appears To Be Reasonable

Aug 23
Hubei Hongyuan Pharmaceutical Technology Co., Ltd.'s (SZSE:301246) P/S Still Appears To Be Reasonable

Hubei Hongyuan Pharmaceutical Technology's (SZSE:301246) Soft Earnings Are Actually Better Than They Appear

Apr 29
Hubei Hongyuan Pharmaceutical Technology's (SZSE:301246) Soft Earnings Are Actually Better Than They Appear

Getting In Cheap On Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246) Is Unlikely

Mar 14
Getting In Cheap On Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246) Is Unlikely

Shareholder Returns

301246CN PharmaceuticalsCN Market
7D-8.1%-5.7%-4.5%
1Y-53.6%-8.5%-2.6%

Return vs Industry: 301246 underperformed the CN Pharmaceuticals industry which returned -8.5% over the past year.

Return vs Market: 301246 underperformed the CN Market which returned -2.6% over the past year.

Price Volatility

Is 301246's price volatile compared to industry and market?
301246 volatility
301246 Average Weekly Movement7.6%
Pharmaceuticals Industry Average Movement6.9%
Market Average Movement7.4%
10% most volatile stocks in CN Market11.2%
10% least volatile stocks in CN Market5.2%

Stable Share Price: 301246 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 301246's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20022,075Shuangxi Xuwww.hbhypharm.com

Hubei Hongyuan Pharmaceutical Technology Co., Ltd., together with its subsidiaries, engages in the production and sale of pharmaceutical products in China and internationally. It provides active pharmaceutical ingredients, such as metronidazole, benzoyl metronidazole, dimetrizole, and acyclovir; pharmaceutical intermediates, including glyoxylic acid, 2-methyl imidazole, 2-methyl-5-nitroimidazole, sulfate, triamine, diacetyl guanine, guanine, and diacetylacyclovir; organic chemical raw materials comprising fluoride salts, glyoxal, and oxalic acid; and new energy materials consisting of lithium hexafluorophosphate. The company was founded in 2002 and is headquartered in Huanggang, China.

Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Fundamentals Summary

How do Hubei Hongyuan Pharmaceutical Technology's earnings and revenue compare to its market cap?
301246 fundamental statistics
Market capCN¥5.34b
Earnings (TTM)CN¥57.95m
Revenue (TTM)CN¥1.96b

92.1x

P/E Ratio

2.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
301246 income statement (TTM)
RevenueCN¥1.96b
Cost of RevenueCN¥1.74b
Gross ProfitCN¥217.19m
Other ExpensesCN¥159.24m
EarningsCN¥57.95m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Oct 25, 2024

Earnings per share (EPS)0.15
Gross Margin11.11%
Net Profit Margin2.96%
Debt/Equity Ratio7.3%

How did 301246 perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

34%

Payout Ratio